Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS)
Dana Cavanaugh BSN, RN
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Search for more papers by this authorAlfonso Urbanucci PhD
Prostate Cancer Research Center, Faculty of Medicine and Health Technology and FiCanMid, Tampere University, Tampere, Finland
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
Search for more papers by this authorNihal E. Mohamed PhD
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Search for more papers by this authorAshutosh K. Tewari MBBS
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Search for more papers by this authorCorresponding Author
Mariana Figueiro PhD
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Department of Population Health Science and Policy, Light and Health Research Center, Mount Sinai Health, New York, New York, USA
Correspondence Natasha Kyprianou, MBBS, PhD and Mariana Figueiro, PhD, Tisch Cancer Institute at Mount Sinai, 1425 Madison Ave, New York, NY 10029, USA.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Natasha Kyprianou MBBS, PhD
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Correspondence Natasha Kyprianou, MBBS, PhD and Mariana Figueiro, PhD, Tisch Cancer Institute at Mount Sinai, 1425 Madison Ave, New York, NY 10029, USA.
Email: [email protected] and [email protected]
Search for more papers by this authorDana Cavanaugh BSN, RN
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Search for more papers by this authorAlfonso Urbanucci PhD
Prostate Cancer Research Center, Faculty of Medicine and Health Technology and FiCanMid, Tampere University, Tampere, Finland
Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
Search for more papers by this authorNihal E. Mohamed PhD
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Search for more papers by this authorAshutosh K. Tewari MBBS
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Search for more papers by this authorCorresponding Author
Mariana Figueiro PhD
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Department of Population Health Science and Policy, Light and Health Research Center, Mount Sinai Health, New York, New York, USA
Correspondence Natasha Kyprianou, MBBS, PhD and Mariana Figueiro, PhD, Tisch Cancer Institute at Mount Sinai, 1425 Madison Ave, New York, NY 10029, USA.
Email: [email protected] and [email protected]
Search for more papers by this authorCorresponding Author
Natasha Kyprianou MBBS, PhD
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Tisch Cancer Institute at Mount Sinai, New York, New York, USA
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Correspondence Natasha Kyprianou, MBBS, PhD and Mariana Figueiro, PhD, Tisch Cancer Institute at Mount Sinai, 1425 Madison Ave, New York, NY 10029, USA.
Email: [email protected] and [email protected]
Search for more papers by this authorAbstract
Background
Benign prostatic hyperplasia (BPH) is the most common urologic disease in aging males, affecting 50% of men over 50 and up to 80% of men over 80 years old. Its negative impact on health-related quality of life implores further investigation into its risk factors and strategies for effective management. Although the exact molecular mechanisms underlying pathophysiological onset of BPH are poorly defined, the current hypothesized contributors to BPH and lower urinary tract symptoms (LUTS) include aging, inflammation, metabolic syndrome, and hormonal changes. These processes are indirectly influenced by circadian rhythm disruption. In this article, we review the recent evidence on the potential association of light changes/circadian rhythm disruption and the onset of BPH and impact on treatment.
Methods
A narrative literature review was conducted using PubMed and Google Scholar to identify supporting evidence. The articles referenced ranged from 1975 to 2023.
Results
A clear relationship between BPH/LUTS and circadian rhythm disruption is yet to be established. However, common mediators influence both diseases, including proinflammatory states, metabolic syndrome, and hormonal regulation that can be asserted to circadian disruption. Some studies have identified a possible relationship between general LUTS and sleep disturbance, but little research has been done on the medical management of these diseases and how circadian rhythm disruption further affects treatment outcomes.
Conclusions
There is evidence to implicate a relationship between BPH/LUTS and circadian rhythm disruptions. However, there is scarce literature on potential specific link in medical management of the disease and treatment outcomes with circadian rhythm disruption. Further study is warranted to provide BPH patients with insights into circadian rhythm directed appropriate interventions.
CONFLICT OF INTEREST STATEMENT
The authors declare no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available in PubMed at https://pubmed.ncbi.nlm.nih.gov/. These data were derived from the following resources available in the public domain:- PubMed, https://pubmed.ncbi.nlm.nih.gov/- Google Scholar, https://scholar.google.com/.
REFERENCES
- 1Ayangbesan A, Kavoussi N. Racial disparities in diagnosis and management of benign prostatic hyperplasia: a review. Curr Urol Rep. 2022; 23(11): 297-302. doi:10.1007/s11934-022-01118-5
- 2De Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016; 13(10): 613-626. doi:10.1038/nrurol.2016.168
- 3Awedew AF, Han H, Abbasi B, et al.The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longevity. 2022; 3(11): e754-e776. doi:10.1016/S2666-7568(22)00213-6
- 4Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impotence Res. 2008; 20(suppl 3): S11-S18. doi:10.1038/ijir.2008.55
- 5Russo GI, Urzì D, Cimino S. Chapter 1—epidemiology of LUTS and BPH. In: G Morgia, GI Russo, eds. Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia. Academic Press; 2018: 1-14.
10.1016/B978-0-12-811397-4.00001-9 Google Scholar
- 6McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185(5): 1793-1803. doi:10.1016/j.juro.2011.01.074
- 7Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003; 61(1): 119-126. doi:10.1016/s0090-4295(02)02114-3
- 8Nachawati D, Patel JB. Alpha Blockers. StatPearls; 2023.
- 9Mansbart F, Kienberger G, Sönnichsen A, Mann E. Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr. 2022; 22(1): 771. doi:10.1186/s12877-022-03415-7
- 10Salisbury BH, Tadi P. 5 Alpha Reductase Inhibitors. StatPearls; 2023.
- 11Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol. 2011; 18(suppl): 14-19.
- 12Kim EH, Brockman JA, Andriole GL. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol. 2018; 5(1): 28-32. doi:10.1016/j.ajur.2017.11.005
- 13Lee KL, Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol. 2004; 172(5 Pt 1): 1784-1791. doi:10.1097/01.ju.0000133655.71782.14
- 14Ho CKM, Habib FK. Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol. 2011; 8(1): 29-41. doi:10.1038/nrurol.2010.207
- 15Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl. 2010; 33(3): 475-488. doi:10.1111/j.1365-2605.2009.00972.x
- 16He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis. 2016; 19(1): 7-13. doi:10.1038/pcan.2015.43
- 17Wittert G. The relationship between sleep disorders and testosterone. Curr Op Endocrinol, Diabetes Obesity. 2014; 21(3): 239-243. doi:10.1097/MED.0000000000000069
- 18Bishehsari F, Voigt RM, Keshavarzian A. Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer. Nat Rev Endocrinol. 2020; 16(12): 731-739. doi:10.1038/s41574-020-00427-4
- 19Zee PC, Attarian H, Videnovic A. Circadian rhythm abnormalities. CONTINUUM: Lifelong Learn Neurol. 2013; 19(1 Sleep Disorders): 132-147. doi:10.1212/01.CON.0000427209.21177.aa
10.1212/01.CON.0000427209.21177.aa Google Scholar
- 20Hofstra WA, de Weerd AW. How to assess circadian rhythm in humans: a review of literature. Epilep Behavior: E&B. 2008; 13(3): 438-444. doi:10.1016/j.yebeh.2008.06.002
- 21Vitaterna MH, Takahashi JS, Turek FW. Overview of circadian rhythms. Alcohol Research Health. 2001; 25(2): 85-93.
- 22Yamazaki S, Numano R, Abe M, et al. Resetting central and peripheral circadian oscillators in transgenic rats. Science. 2000; 288(5466): 682-685. doi:10.1126/science.288.5466.682
- 23Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet. 2008; 9(10): 764-775. doi:10.1038/nrg2430
- 24Takahashi JS. Transcriptional architecture of the mammalian circadian clock. Nat Rev Genet. 2017; 18(3): 164-179. doi:10.1038/nrg.2016.150
- 25James SM, Honn KA, Gaddameedhi S, Van Dongen HPA. Shift work: disrupted circadian rhythms and sleep-implications for health and well-being. Curr Sleep Med Rep. 2017; 3(2): 104-112. doi:10.1007/s40675-017-0071-6
- 26Czeisler CA. The effect of light on the human circadian pacemaker. Ciba Found Symp. 1995; 183: 254-290. Discussion 290-302. doi:10.1002/9780470514597.ch14
- 27Brown GM. Chronopharmacological actions of the pineal gland. Drug Metabol Drug Interact. 1990; 8(3-4): 189-201.
- 28Chakrabarti S, Michor F. Circadian clock effects on cellular proliferation: insights from theory and experiments. Curr Opin Cell Biol. 2020; 67: 17-26. doi:10.1016/j.ceb.2020.07.003
- 29Potter GDM, Skene DJ, Arendt J, Cade JE, Grant PJ, Hardie LJ. Circadian rhythm and sleep disruption: causes, metabolic consequences, and countermeasures. Endocr Rev. 2016; 37(6): 584-608. doi:10.1210/er.2016-1083
- 30Savvidis C, Koutsilieris M. Circadian rhythm disruption in cancer biology. Mol Med. 2012; 18(1): 1249-1260. doi:10.2119/molmed.2012.00077
- 31Thosar SS, Butler MP, Shea SA. Role of the circadian system in cardiovascular disease. J Clin Invest. 2018; 128(6): 2157-2167. doi:10.1172/JCI80590
- 32Daiber A, Frenis K, Kuntic M, et al. Redox regulatory changes of circadian rhythm by the environmental risk factors traffic noise and air pollution. Antioxid Redox Sig. 2022; 37(10-12): 679-703. doi:10.1089/ars.2021.0272
- 33Comperatore CA, Krueger GP. Circadian rhythm desynchronosis, jet lag, shift lag, and coping strategies. Occup Med Apr. 1990; 5(2): 323-341.
- 34Gander P, Mulrine HM, van den Berg MJ, et al. Does the circadian clock drift when pilots fly multiple transpacific flights with 1- to 2-day layovers? Chronobiol Int. 2016; 33(8): 982-994. doi:10.1080/07420528.2016.1189430
- 35Lunn RM, Blask DE, Coogan AN, et al. Health consequences of electric lighting practices in the modern world: a report on the National Toxicology Program's workshop on shift work at night, artificial light at night, and circadian disruption. Sci Total Environ. 2017; 607-608: 1073-1084. doi:10.1016/j.scitotenv.2017.07.056
- 36Kryger MH, Roth T, Dement WC. Principles and Practice of Sleep Medicine E-Book. Elsevier Health Sciences; 2010.
- 37Pallesen S, Bjorvatn B, Waage S, Harris A, Sagoe D. Prevalence of shift work disorder: a systematic review and meta-analysis. Front Psychol. 2021; 12:638252. doi:10.3389/fpsyg.2021.638252
- 38 American Academy of Sleep Medicine. International classification of sleep disorders—third edition (ICSD-3). AASM Resour Libr2014. 2313.
- 39Wright Jr. KP, Bogan RK, Wyatt JK. Shift work and the assessment and management of shift work disorder (SWD). Sleep Med Rev. 2013; 17(1): 41-54. doi:10.1016/j.smrv.2012.02.002
- 40Vyas MV, Garg AX, Iansavichus AV, et al. Shift work and vascular events: systematic review and meta-analysis. BMJ. 2012; 345:e4800. doi:10.1136/bmj.e4800
- 41Wang F, Zhang L, Zhang Y, et al. Meta-analysis on night shift work and risk of metabolic syndrome. Obesity Rev. 2014; 15(9): 709-720. doi:10.1111/obr.12194
- 42Kubo T, Ozasa K, Mikami K, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan Collaborative Cohort Study. Am J Epidemiol. 2006; 164(6): 549-555. doi:10.1093/aje/kwj232
- 43Knutsson A, Bøggild H. Gastrointestinal disorders among shift workers. Scand J Work Environ Health. 2010; 36(2): 85-95.
- 44Mahoney MM. Shift work, jet lag, and female reproduction. Int J Endocrinol. 2010; 2010: 1-9. doi:10.1155/2010/813764
- 45Drake CL, Roehrs T, Richardson G, Walsh JK, Roth T. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep. 2004; 27(8): 1453-1462. doi:10.1093/sleep/27.8.1453
- 46Brown JP, Martin D, Nagaria Z, Verceles AC, Jobe SL, Wickwire EM. Mental health consequences of shift work: an updated review. Curr Psychiatry Rep. 2020; 22(2): 7. doi:10.1007/s11920-020-1131-z
- 47Walker 2nd WH, Walton JC, DeVries AC, Nelson RJ. Circadian rhythm disruption and mental health. Transl Psychiatry. 2020; 10(1): 28. doi:10.1038/s41398-020-0694-0
- 48Halperin D. Environmental noise and sleep disturbances: a threat to health? Sleep Sci. 2014; 7(4): 209-212. doi:10.1016/j.slsci.2014.11.003
- 49Patrick DM, Harrison DG. Nocturnal noise knocks NOS by Nox: mechanisms underlying cardiovascular dysfunction in response to noise pollution. Eur Heart J. 2018; 39(38): 3540-3542. doi:10.1093/eurheartj/ehy431
- 50Falchi F, Cinzano P, Duriscoe D, et al. The new world atlas of artificial night sky brightness. Sci Adv. 2016; 2(6):e1600377. doi:10.1126/sciadv.1600377
- 51Zhu WZ, He QY, Feng DC, Wei Q, Yang L. Circadian rhythm in prostate cancer: time to take notice of the clock. Asian J Androl. 2023; 25(2): 184-191. doi:10.4103/aja202255
- 52Cao Q, Gery S, Dashti A, et al. A role for the clock gene per1 in prostate cancer. Cancer Res. 2009; 69(19): 7619-7625. doi:10.1158/0008-5472.CAN-08-4199
- 53Hadadi E, Acloque H. Role of circadian rhythm disorders on EMT and tumour-immune interactions in endocrine-related cancers. Endocr Relat Cancer. 2021; 28(2): R67-R80. doi:10.1530/ERC-20-0390
- 54Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res. 2010; 49(1): no. doi:10.1111/j.1600-079X.2010.00767.x
- 55Linder S, Hoogstraat M, Stelloo S, et al. Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence. Cancer Discovery. 2022; 12(9): 2074-2097. doi:10.1158/2159-8290.CD-21-0576
- 56Adams KL, Castanon-Cervantes O, Evans JA, Davidson AJ. Environmental circadian disruption elevates the IL-6 response to lipopolysaccharide in blood. J Biol Rhythms. 2013; 28(4): 272-277. doi:10.1177/0748730413494561
- 57Gombert M, Carrasco-Luna J, Pin-Arboledas G, Codoñer-Franch P. The connection of circadian rhythm to inflammatory bowel disease. Transl Res. 2019; 206: 107-118. doi:10.1016/j.trsl.2018.12.001
- 58Polidarová L, Houdek P, Sumová A. Chronic disruptions of circadian sleep regulation induce specific proinflammatory responses in the rat colon. Chronobiol Int. 2017; 34(9): 1273-1287. doi:10.1080/07420528.2017.1361436
- 59Puttonen S, Viitasalo K, Härmä M. Effect of shiftwork on systemic markers of inflammation. Chronobiol Int. 2011; 28(6): 528-535. doi:10.3109/07420528.2011.580869
- 60Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016; 13(2): 108-119. doi:10.1038/nrurol.2015.301
- 61Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640-1645. doi:10.1161/CIRCULATIONAHA.109.192644
- 62De Nunzio C, Brassetti A, Proietti F, Deroma M, Esperto F, Tubaro A. Metabolic syndrome and smoking are associated with an increased risk of nocturia in male patients with benign prostatic enlargement. Prostate Cancer Prostatic Dis. 2018; 21(2): 287-292. doi:10.1038/s41391-017-0003-z
- 63Hernández-García J, Navas-Carrillo D, Orenes-Piñero E. Alterations of circadian rhythms and their impact on obesity, metabolic syndrome and cardiovascular diseases. Crit Rev Food Sci Nutr. 2020; 60(6): 1038-1047. doi:10.1080/10408398.2018.1556579
- 64Figueiro MG, Radetsky L, Plitnick B, Rea MS. Glucose tolerance in mice exposed to light-dark stimulus patterns mirroring dayshift and rotating shift schedules. Sci Rep. 2017; 7:40661. doi:10.1038/srep40661
- 65Xiong Y, Zhang F, Wu C, et al. The circadian syndrome predicts lower urinary tract symptoms suggestive of benign prostatic hyperplasia better than metabolic syndrome in aging males: a 4-year follow-up study. Front Med. 2021; 8:715830. doi:10.3389/fmed.2021.715830
- 66Zimmet P, Alberti KGMM, Stern N, et al. The circadian syndrome: is the metabolic syndrome and much more. J Intern Med. 2019; 286(2): 181-191. doi:10.1111/joim.12924
- 67Kim JW, Moon YT, Kim KD. Nocturia: the circadian voiding disorder. Investig Clin Urol. 2016; 57(3): 165-173. doi:10.4111/icu.2016.57.3.165
- 68Firsov D, Bonny O. Circadian rhythms and the kidney. Nature Rev Nephrol. 2018; 14(10): 626-635. doi:10.1038/s41581-018-0048-9
- 69Negoro H, Kanematsu A, Yoshimura K, Ogawa O. Chronobiology of micturition: putative role of the circadian clock. J Urol. 2013; 190(3): 843-849. doi:10.1016/j.juro.2013.02.024
- 70Klerman EB. Clinical aspects of human circadian rhythms. J Biol Rhythms. 2005; 20(4): 375-386. doi:10.1177/0748730405278353
- 71Birder LA, Van Kerrebroeck PEV. Pathophysiological mechanisms of nocturia and nocturnal polyuria: the contribution of cellular function, the urinary bladder urothelium, and circadian rhythm. Urology. 2019; 133S: 14-23. doi:10.1016/j.urology.2019.07.020
- 72George CPL, Messerli FH, Genest J, et al. Diurnal variation of plasma vasopressin in man. J Clin Endocrinol Metabolism. 1975; 41(2): 332-338. doi:10.1210/jcem-41-2-332
- 73Araujo AB, Yaggi HK, Yang M, McVary KT, Fang SC, Bliwise DL. Sleep related problems and urological symptoms: testing the hypothesis of bidirectionality in a longitudinal, population based study. J Urol. 2014; 191(1): 100-106. doi:10.1016/j.juro.2013.07.011
- 74Scovell JM, Pastuszak AW, Slawin J, Badal J, Link RE, Lipshultz LI. Impaired sleep quality is associated with more significant lower urinary tract symptoms in male shift workers. Urology. 2017; 99: 197-202. doi:10.1016/j.urology.2016.05.076
- 75Li Y, Zhou X, Qiu S, et al. Association of sleep quality with lower urinary tract symptoms/benign prostatic hyperplasia among men in China: a cross-sectional study. Front Aging Neurosci. 2022; 14:938407. doi:10.3389/fnagi.2022.938407
- 76Cakir OO, McVary KT. LUTS and sleep disorders: emerging risk factor. Curr Urol Rep. 2012; 13(6): 407-412. doi:10.1007/s11934-012-0281-x
- 77Helfand BT, McVary KT, Meleth S, et al. The relationship between lower urinary tract symptom severity and sleep disturbance in the CAMUS trial. J Urol. 2011; 185(6): 2223-2228. doi:10.1016/j.juro.2011.02.012
- 78Przydacz M, Skalski M, Sobanski J, et al. Association between lower urinary tract symptoms and sleep quality of patients with depression. Medicina. 2021; 57(4):394. doi:10.3390/medicina57040394
- 79Copinschi G, Caufriez A. Sleep and hormonal changes in aging. Endocrinol Metab Clin North Am. 2013; 42(2): 371-389. doi:10.1016/j.ecl.2013.02.009
- 80Axelsson J, Ingre M, Åkerstedt T, Holmbäck U. Effects of acutely displaced sleep on testosterone. J Clin Endocrinol Metabolism. 2005; 90(8): 4530-4535. doi:10.1210/jc.2005-0520
- 81Mearini L, Costantini E, Zucchi A, et al. Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int. 2008; 80(2): 134-140. doi:10.1159/000112602
- 82Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and benign prostatic hyperplasia. Sexual Med Rev. 2019; 7(2): 259-271. doi:10.1016/j.sxmr.2018.10.006
- 83Kristal AR, Arnold KB, Schenk JM, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol. 2007; 177(4): 1395-1400. Quiz 1591. doi:10.1016/j.juro.2006.11.065
- 84Wei JT, Schottenfeld D, Cooper K, et al. The natural history of lower urinary tract symptoms in Black American men: relationships with aging, prostate size, flow rate and bothersomeness. J Urol. 2001; 165(5): 1521-1525.
- 85Roberts RO, Chute CG, Rhodes T, et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology. 1994; 43(5): 621-628. doi:10.1016/0090-4295(94)90174-0
- 86Hall SA, Link CL, Hu JC, Eggers PW, McKinlay JB. Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample. BJU Int. 2009; 104(11): 1680-1688. doi:10.1111/j.1464-410X.2009.08686.x
- 87Patel PM, Sweigert SE, Nelson M, et al. Disparities in benign prostatic hyperplasia progression: predictors of presentation to the emergency department in urinary retention. J Urol. 2020; 204(2): 332-336. doi:10.1097/JU.0000000000000787
- 88Fowke JH, Murff HJ, Signorello LB, Lund L, Blot WJ. Race and socioeconomic status are independently associated with benign prostatic hyperplasia. J Urol. 2008; 180: 2091-2096. doi:10.1016/j.juro.2008.07.059
- 89Gill H. Racial disparities in the treatment of benign prostatic hyperplasia. Med Surg Urol. 2015; 4:157. doi:10.4172/2168-9857.1000157
10.4172/2168-9857.1000157 Google Scholar
- 90Hoke GP, McWilliams GW. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med. 2008; 121(8 suppl 2): S3-S10. doi:10.1016/j.amjmed.2008.05.021
- 91Joseph MA. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003; 157(10): 906-914. doi:10.1093/aje/kwg051
- 92Johnson TV, Abbasi A, Ehrlich SS, et al. Patient misunderstanding of the individual questions of the American Urological Association symptom score. J Urol. 2008; 179(6): 2291-2295. Discussion 2294-2295. doi:10.1016/j.juro.2008.01.140
- 93Wong MD, Shapiro MF, Boscardin WJ, Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002; 347(20): 1585-1592. doi:10.1056/NEJMsa012979
- 94Skelly AH. Type 2 diabetes mellitus. Nurs Clin North Am. 2006; 41(4): 531-547. doi:10.1016/j.cnur.2006.07.011
- 95Stamatakis KA, Kaplan GA, Roberts RE. Short sleep duration across income, education, and race/ethnic groups: population prevalence and growing disparities during 34 years of follow-up. Ann Epidemiol. 2007; 17(12): 948-955. doi:10.1016/j.annepidem.2007.07.096
- 96Ertel KA, Berkman LF, Buxton OM. Socioeconomic status, occupational characteristics, and sleep duration in African/Caribbean immigrants and US White health care workers. Sleep. 2011; 34(4): 509-518. doi:10.1093/sleep/34.4.509
- 97Huang SJ, Sehgal NJ. Association of historic redlining and present-day health in Baltimore. PLoS One. 2022; 17(1):e0261028. doi:10.1371/journal.pone.0261028
- 98Johnson DA, Lisabeth L, Hickson D, et al. The social patterning of sleep in African Americans: associations of socioeconomic position and neighborhood characteristics with sleep in the Jackson Heart Study. Sleep. 2016; 39(9): 1749-1759. doi:10.5665/sleep.6106
- 99Seltenrich N. Inequality of noise exposures: a portrait of the United States. Environ Health Perspect. 2017; 125(9):094003. doi:10.1289/EHP2471
- 100Ghosh-Dastidar B, Cohen D, Hunter G, et al. Distance to store, food prices, and obesity in urban food deserts. Am J Prev Med. 2014; 47(5): 587-595. doi:10.1016/j.amepre.2014.07.005
- 101Duffy JF, Abbott SM, Burgess HJ, et al. Workshop report. Circadian rhythm sleep-wake disorders: gaps and opportunities. Sleep. 2021; 44(5):1. doi:10.1093/sleep/zsaa281
